Home / Market News / $BMEA

$BMEA news and market catalysts

The 17 most recent market catalysts affecting $BMEA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

17 catalysts 8 high impact 5 bullish 6 bearish Biotechnology
Nov 11, 2026 Corporate Catalyst Bearish Impact 75
Biomea Fusion Reports Third Quarter 2026 Financial Results and Business Update
Biomea Fusion's Q3 2026 earnings report shows a substantial reduction in net loss, from $16.4 million to $6.2 million year-over-year, primarily due to decreased R&D spending. This …
Nov 3, 2026 Corporate Catalyst Neutral Impact 55
Biomea Fusion, Inc. Scheduled to Announce Q3 2026 Financial Results
This 8-K filing announces the scheduled date for Biomea Fusion, Inc.'s Q3 2026 financial results, set for November 3, 2026, at 7:00 AM ET. The market anticipates an EPS of -$0.21 f…
Oct 14, 2026 Corporate Catalyst Neutral Impact 95
What’s Going On With Biomea Fusion (BMEA) Stock After Hours?
Biomea Fusion released Phase 1 results for BMF-650, its GLP-1 receptor agonist for weight management. While the drug demonstrated good safety and tolerability, the weight reduction…
Oct 13, 2026 Corporate Catalyst Bearish Impact 85
Biomea Fusion shares are trading lower after the company announced Phase 1 GLP-131 clinical trial results for BMF-650.
The headline indicates a significant corporate catalyst for Biomea Fusion. Phase 1 clinical trial results, especially for a drug like BMF-650 in the GLP-1 space, are critical early…
Oct 13, 2026 Corporate Catalyst Bullish Impact 75
Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?
Biomea Fusion's announcement of upcoming Phase I results for its GLP-1 candidate BMF-650 is a significant event for the company. The after-hours stock climb suggests that investors…
Oct 12, 2026 Corporate Catalyst Bullish Impact 85
Biomea Fusion shares are trading higher after the company announced that it will report results from its Phase I GLP-131 clinical study evaluating BMF-650 on October 13, 2026.
This headline represents a significant corporate catalyst for Biomea Fusion. The upcoming release of Phase I clinical trial results for a GLP-131 drug is a major event for a biotec…
Oct 12, 2026 Corporate Catalyst Neutral Impact 65
Biomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13
Biomea Fusion has announced a specific date, October 13, 2026, for reporting the results of its Phase I GLP-131 clinical study for BMF-650. This is a significant event for the comp…
Oct 7, 2026 Corporate Catalyst Neutral Impact 55
Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10
Brookline Capital's initiation of coverage on Biomea Fusion with a 'Buy' rating and a $10 price target is a positive development for the company. Analyst coverage can increase visi…
Sep 23, 2026 Corporate Catalyst Bearish Impact 92
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion's decision to terminate its public offering is a strong negative signal, suggesting the company either couldn't secure favorable terms or faced insufficient demand, p…
Sep 23, 2026 Corporate Catalyst Bearish Impact 85
Biomea Fusion shares are trading lower after the company announced the termination of its proposed public offering of securities.
The termination of a proposed public offering is a significant negative corporate catalyst for Biomea Fusion. It suggests either a lack of investor demand at the desired price, or …
Sep 23, 2026 Corporate Catalyst Bearish Impact 85
Biomea Fusion Shares Fall 19% After Hours: Here’s Why
Biomea Fusion announced an underwritten public offering of common stock and pre-funded warrants after market close. This type of offering is a common way for clinical-stage biotech…
Sep 22, 2026 Corporate Catalyst Bearish Impact 85
Biomea Fusion shares are trading lower after the company announced it now expects topline data from Phase 1 GLP-131 trial for BMF-650 in October 2026. Also, the company announced a proposed public offering.
This headline represents a significant negative corporate catalyst for Biomea Fusion. The delay in topline data for their GLP-131 trial from an unspecified earlier date to October …
Sep 22, 2026 Corporate Catalyst Neutral Impact 75
Biomea Fusion Announces Proposed Public Offering Of Securities; Terms Not Disclosed
This announcement is a significant corporate catalyst for Biomea Fusion. A public offering, especially with undisclosed terms, typically leads to short-term downward pressure on th…
Sep 22, 2026 Corporate Catalyst Neutral Impact 75
Biomea Fusion Says Topline Data From Phase 1 Obesity Trial Of BMF-650 Now Expected In October, Pushed From Q3
Biomea Fusion has informed the market that the topline data for its Phase 1 obesity trial of BMF-650, previously anticipated in Q3, will now be released in October. This delay, whi…
Aug 24, 2026 Corporate Catalyst Bullish Impact 75
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Biomea Fusion's announcement of completing patient enrollment for its COVALENT-211 Phase II trial is a significant operational milestone for the company. This indicates progress in…
Aug 24, 2026 Corporate Catalyst Bullish Impact 85
Biomea Fusion shares are trading higher after the company announced the completion of enrollment in COVALENT-211 Phase II clinical trial evaluating icovamenib in insulin-deficient Type 2 diabetes.
This headline is a significant corporate catalyst for Biomea Fusion (BMEA). Completing Phase II enrollment for a drug targeting insulin-deficient Type 2 diabetes is a crucial miles…
Aug 13, 2026 Corporate Catalyst Bullish Impact 75
Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults
The dosing of the first participant in Biomea Fusion's OPAL study arm is a key development for the company, moving their icovamenib + semaglutide combination therapy forward. A pos…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.